0 citations
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting
British Journal of Dermatology2020
Citations Over TimeTop 16% of 2020 papers
Kim S Thomas, Christian Apfelbacher, Joanne R Chalmers, Eric L. Simpson, Phyllis I. Spuls, Louise A. A. Gerbens, Hywel C Williams, Jochen Schmitt, Michaela Gabes, Laura Howells, Beth Stuart, Erin E. Grinich, T. Pawlitschek, T. Burton, L. Howie, A. Gadkari, Laurent Eckert, T. Ebata, Maarten Boers, Hidehisa Saeki, T. Nakahara, Norito Katoh
Abstract
For now, the core outcome set for clinical trials in atopic eczema is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.
Related Papers
- → Real‐world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood(2024)10 cited
- → Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis(2022)9 cited
- → Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients(2024)8 cited
- → 26691 Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5(2021)1 cited
- → 26670 The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in a baricitinib phase 3 study, BREEZE-AD5(2021)